As of 11 March 2019, the European Medicines Agency (EMA) is operating from Amsterdam. EMA's seat formally changes from London to Amsterdam on 30 March. A week after starting operations from Amsterdam, EMA was visited by European Commissioner for Health and Food Safety, Mr. Andriukaitis, and Minister for Medical Care of the Netherlands, Mr. Bruins. At its first meeting in Amsterdam, the EMA Management Board re-elected Christa Wirthumer-Hoche as its chair. Dr. Wirthumer-Hoche is also the head of the Austrian Medicines and Medical Devices Agency.

Brief update on the EMA activities in March:

  • New time zone: from 11 March 2019, the EMA's business hours and submission deadlines, switched from Greenwich Mean Time (GMT) to Central European Time (CET).
  • EMA published a Q&A document on the preparatory work EU authorities are doing to prevent medicine shortages due to the UK's withdrawal from the EU (Brexit).
  • EMA published the annual report on Eudravigilance, the EU system for managing and analyzing information on suspected adverse reactions to medicines.
  • As EMA's resources are diverted to prepare for Brexit and the EMA relocation, EMA will continue to operate under business continuity conditions, to safeguard core activities related to the evaluation and supervision of medicinal products.